Literature DB >> 8411389

Anoxia-inducible rat VL30 elements and their relationship to ras-containing sarcoma viruses.

B A Firulli1, G R Anderson, D L Stoler, S D Estes.   

Abstract

VL30 elements are associated with cancer by their overexpression in rodent malignancies, their induction in a fibroblast response to anoxia which shares features with the malignant phenotype, and their presence recombined into Harvey murine sarcoma virus (HaSV) and Kirsten murine sarcoma virus. These sarcoma viruses contain ras oncogenes flanked on both sides by retrotransposon VL30 element sequences, in turn flanked by mouse leukemia virus sequences. Three very basic questions have existed about the VL30 element sequences found in sarcoma viruses: (i) how did they become recombined, (ii) what are their exact boundaries, and (iii) why are they there? To help decipher the nature of VL30 elements in sarcoma viruses, we examined VL30 clones isolated from an anoxic fibroblast cDNA library and independently by polymerase chain reaction cloning from rat cell DNA. Sequence comparisons with HaSV revealed that HaSV was formed by the substitution of 0.7 kb of VL30 sequences by 0.9 kb of c-Ha-ras sequences, with this event possibly facilitated by the presence of an identical Alu-like repeat found upstream of the 5' recombination point in both the VL30 element and c-Ha-ras. Recombination occurred 42 bases beyond the Alu-like sequences in VL30 and 1596 bases beyond them in c-Ha-ras, at position 926 of HaSV. The 3' ras-VL30 recombination event in HaSV occurred within a seven-base region of shared sequence identity, between HaSV bases 1825 and 1825 and 1831. Recombination between Moloney leukemia virus (MoLV) and VL30 appears to have occurred at a point corresponding to base 218 or 219 of MoLV and was near a TAR-like VL30 sequence; such recombination at the 3' end was between positions 7445 and 7456 of MoLV (HaSV positions 4694 to 4703). Kirsten murine sarcoma virus was found to be closely analogous to HaSV, and limited similar features were also seen with Rasheed sarcoma virus.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8411389      PMCID: PMC238132     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  AN UNIDENTIFIED VIRUS WHICH CAUSES THE RAPID PRODUCTION OF TUMOURS IN MICE.

Authors:  J J HARVEY
Journal:  Nature       Date:  1964-12-12       Impact factor: 49.962

2.  Rapid and selective alterations in the expression of cellular genes accompany conditional transcription of Ha-v-ras in NIH 3T3 cells.

Authors:  R D Owen; M C Ostrowski
Journal:  Mol Cell Biol       Date:  1987-07       Impact factor: 4.272

3.  Improved tools for biological sequence comparison.

Authors:  W R Pearson; D J Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

4.  Promoter and enhancer activities of long terminal repeats associated with cellular retrovirus-like (VL30) elements.

Authors:  G Rotman; A Itin; E Keshet
Journal:  Nucleic Acids Res       Date:  1986-01-24       Impact factor: 16.971

5.  Complete nucleotide sequence of a mouse VL30 retro-element.

Authors:  S E Adams; P D Rathjen; C A Stanway; S M Fulton; M H Malim; W Wilson; J Ogden; L King; S M Kingsman; A J Kingsman
Journal:  Mol Cell Biol       Date:  1988-08       Impact factor: 4.272

6.  Isolation of cellular genes differentially expressed in mouse NIH 3T3 cells and a simian virus 40-transformed derivative: growth-specific expression of VL30 genes.

Authors:  K Singh; S Saragosti; M Botchan
Journal:  Mol Cell Biol       Date:  1985-10       Impact factor: 4.272

7.  Harvey murine sarcoma virus: influences of coding and noncoding sequences on cell transformation in vitro and oncogenicity in vivo.

Authors:  T J Velu; W C Vass; D R Lowy; P E Tambourin
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

8.  Harvey sarcoma virus genome contains no extensive sequences unrelated to those of other retroviruses except ras.

Authors:  K F Manly; G R Anderson; D L Stoler
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

9.  Harvey ras genes transform without mutant codons, apparently activated by truncation of a 5' exon (exon -1).

Authors:  K Cichutek; P H Duesberg
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

10.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.

Authors:  W J Muller; E Sinn; P K Pattengale; R Wallace; P Leder
Journal:  Cell       Date:  1988-07-01       Impact factor: 41.582

View more
  6 in total

1.  Acutely transforming retrovirus expressing Nras generated from HT-1080 fibrosarcoma cells infected with the human retrovirus XMRV.

Authors:  Michael J Metzger; A Dusty Miller
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

2.  A splicing enhancer in the 3'-terminal c-H-ras exon influences mRNA abundance and transforming activity.

Authors:  D Y Hwang; J B Cohen
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

3.  An internal ribosomal entry signal in the rat VL30 region of the Harvey murine sarcoma virus leader and its use in dicistronic retroviral vectors.

Authors:  C Berlioz; C Torrent; J L Darlix
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

4.  Characterization of gene expression in resting and activated mast cells.

Authors:  H Chen; M Centola; S F Altschul; H Metzger
Journal:  J Exp Med       Date:  1998-11-02       Impact factor: 14.307

5.  Anoxic induction of a sarcoma virus-related VL30 retrotransposon is mediated by a cis-acting element which binds hypoxia-inducible factor 1 and an anoxia-inducible factor.

Authors:  S D Estes; D L Stoler; G R Anderson
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

6.  Genetic analysis of the rat leukemia virus: influence of viral sequences in transduction of the c-ras proto-oncogene and expression of its transforming activity.

Authors:  S Y Lee; T M Howard; S Rasheed
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.